Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Marin
David
D
Marktel
Sarah
S
Foot
Nicola
N
Bua
Marco
M
Goldman
John M
JM
Apperley
Jane F
JF
D001549:Benzamides; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity*; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity*; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate